ValuEngine Lowers Verastem, Inc. (VSTM) to Sell
ValuEngine lowered shares of Verastem, Inc. (NASDAQ:VSTM) from a hold rating to a sell rating in a research report released on Friday.
VSTM has been the topic of a number of other research reports. Cann reaffirmed a buy rating and issued a $6.00 target price on shares of Verastem in a research report on Monday, June 26th. HC Wainwright set a $7.00 target price on Verastem and gave the company a buy rating in a research report on Thursday, August 10th. Zacks Investment Research downgraded Verastem from a hold rating to a sell rating in a research report on Saturday, August 12th. Cantor Fitzgerald reaffirmed a hold rating and issued a $2.00 target price on shares of Verastem in a research report on Thursday, May 11th. Finally, Jefferies Group LLC reaffirmed a hold rating and issued a $1.50 target price on shares of Verastem in a research report on Wednesday, June 28th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of Hold and an average target price of $4.61.
Verastem (NASDAQ:VSTM) opened at 3.92 on Friday. The firm’s market cap is $145.01 million. Verastem has a one year low of $1.05 and a one year high of $4.67. The stock’s 50 day moving average price is $3.50 and its 200-day moving average price is $2.38.
Verastem (NASDAQ:VSTM) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by $0.02. Analysts forecast that Verastem will post ($1.38) earnings per share for the current year.
Several large investors have recently added to or reduced their stakes in the stock. OxFORD Asset Management LLP acquired a new stake in shares of Verastem in the second quarter valued at about $234,000. Dimensional Fund Advisors LP increased its position in Verastem by 697.6% during the second quarter. Dimensional Fund Advisors LP now owns 289,828 shares of the biopharmaceutical company’s stock worth $632,000 after buying an additional 253,492 shares during the last quarter. Vanguard Group Inc. increased its position in Verastem by 10.3% during the second quarter. Vanguard Group Inc. now owns 1,143,642 shares of the biopharmaceutical company’s stock worth $2,493,000 after buying an additional 107,029 shares during the last quarter. Northern Trust Corp increased its position in Verastem by 40.3% during the second quarter. Northern Trust Corp now owns 73,750 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 21,178 shares during the last quarter. Finally, Artal Group S.A. acquired a new position in Verastem during the second quarter worth approximately $1,090,000. 24.19% of the stock is currently owned by institutional investors and hedge funds.
Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Verastem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.